nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A phase 2 randomized study of TAS-102 versus topotecan or amrubicin in patients requiring second-line chemotherapy for small cell lung cancer refractory or sensitive to frontline platinum-based chemotherapy
|
Scagliotti, Giorgio |
|
2016 |
100 |
C |
p. 20-23 4 p. |
artikel |
2 |
Comparison of survival of chronic obstructive pulmonary disease patients with or without a localized non-small cell lung cancer
|
Jeppesen, Stefan S. |
|
2016 |
100 |
C |
p. 90-95 6 p. |
artikel |
3 |
Contents
|
|
|
2016 |
100 |
C |
p. v-vi nvt p. |
artikel |
4 |
Current patterns of care for patients with extensive stage small cell lung cancer: Survey of US radiation oncologists on their recommendations regarding thoracic consolidation radiotherapy
|
Mitin, Timur |
|
2016 |
100 |
C |
p. 85-89 5 p. |
artikel |
5 |
Depression symptom trends and health domains among lung cancer patients in the CanCORS study
|
Sullivan, D.R. |
|
2016 |
100 |
C |
p. 102-109 8 p. |
artikel |
6 |
Editorial Board
|
|
|
2016 |
100 |
C |
p. iii- 1 p. |
artikel |
7 |
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
|
Neumair, P. |
|
2016 |
100 |
C |
p. 38-44 7 p. |
artikel |
8 |
Evaluation of serum amino acid profiles’ utility in non-small cell lung cancer detection in Polish population
|
Klupczynska, Agnieszka |
|
2016 |
100 |
C |
p. 71-76 6 p. |
artikel |
9 |
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma?
|
Sharkey, Annabel J. |
|
2016 |
100 |
C |
p. 5-13 9 p. |
artikel |
10 |
Immunohistochemical pattern analysis of squamous cell carcinoma: Lung primary and metastatic tumors of head and neck
|
Ichinose, Junji |
|
2016 |
100 |
C |
p. 96-101 6 p. |
artikel |
11 |
Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib
|
Sorensen, Steffen Filskov |
|
2016 |
100 |
C |
p. 77-84 8 p. |
artikel |
12 |
Is VATS lobectomy standard of care for operable non-small cell lung cancer?
|
Vannucci, Fernando |
|
2016 |
100 |
C |
p. 114-119 6 p. |
artikel |
13 |
Microenvironmental changes in the progression from adenocarcinoma in situ to minimally invasive adenocarcinoma and invasive lepidic predominant adenocarcinoma of the lung
|
Naito, Masahito |
|
2016 |
100 |
C |
p. 53-62 10 p. |
artikel |
14 |
Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma
|
Guibert, Nicolas |
|
2016 |
100 |
C |
p. 1-4 4 p. |
artikel |
15 |
Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC
|
Ardizzoni, Andrea |
|
2016 |
100 |
C |
p. 30-37 8 p. |
artikel |
16 |
Retraction to “Ellipticine-induced apoptosis depends on Akt translocation and signaling in lung epithelial cancer cells”
|
Fang, Kang |
|
2016 |
100 |
C |
p. 120- 1 p. |
artikel |
17 |
Scan-associated distress in lung cancer: Quantifying the impact of “scanxiety”
|
Bauml, Joshua M. |
|
2016 |
100 |
C |
p. 110-113 4 p. |
artikel |
18 |
Somatic alterations in lung cancer: Do environmental factors matter?
|
Gibelin, Cécilia |
|
2016 |
100 |
C |
p. 45-52 8 p. |
artikel |
19 |
Standardized uptake value on 18F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs
|
Yoshida, Tatsuya |
|
2016 |
100 |
C |
p. 14-19 6 p. |
artikel |
20 |
The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis
|
Jiang, Tao |
|
2016 |
100 |
C |
p. 63-70 8 p. |
artikel |
21 |
Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor
|
Moon, Seung Hwan |
|
2016 |
100 |
C |
p. 24-29 6 p. |
artikel |